Amgen reduces IMDELLTRA monitoring to 6-8 hours

• Amgen received U.S. FDA approval to update the prescribing information for IMDELLTRA, cutting the recommended monitoring time for the first two treatment doses to 6–8 hours.
• The regulatory update drastically reduces the hospital observation burden for extensive-stage small cell lung cancer patients, who previously faced a 22–24 hour requirement.
• The company stated that the reduced clinical monitoring expectations are expected to lower the logistical treatment complexity for patients and community oncology practices.

Amgen (NASDAQ:AMGN) received U.S. FDA approval to update the prescribing information for IMDELLTRA, reducing the initial monitoring time to 6–8 hours.

The label update decreases the required observation period for the first two treatment doses from the previously mandated 22–24 hours.

Patients receiving the therapy for extensive-stage small cell lung cancer must now undergo a next-day assessment including vital signs after the initial infusions.

The updated guidelines specify that later-cycle monitoring remains at 6–8 hours for the third dose and decreases to two hours from Cycle 5 onward.

The medical guidance still requires patients to remain within one hour of appropriate care for 48 hours after the first two cycle doses.

The company stated the regulatory adjustment is expected to lessen the logistical burden on patients and healthcare facilities administering the cancer treatment.